Anixa, OntoChem advance development of COVID-19 therapeutic

By The Science Advisory Board staff writers

April 5, 2021 -- Anixa Biosciences and OntoChem are progressing to the next stage of development of an antiviral therapy for COVID-19.

The therapy will be orally administered and room-temperature stable. The two firms have completed proof-of-concept animal studies that evaluated potential compounds and compared them with remdesivir.

The firms plan to use combinatorial synthetic medicinal chemistry to evaluate whether potency can be increased and pharmacokinetics optimized. Promising compounds will again be studied, they said. This stage of development will take four to five months.

Anixa, OntoChem identify new anti-SARS-CoV-2 compounds
Anixa Biosciences and OntoChem have identified 26 additional compounds that target the main protease inhibitors of SARS-CoV-2.
Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter